- Prempro news are updated once a hour
- We deliver news from more than 500 sources on Prempro
NewsAdvertisers: |
Consumer Reports Questions FDA Prescription Drug Approval Process... APM's "Marketplace Morning Report" on Wednesday reported on the report. The segment includes comments from Alan Goldhammer, associate vice president of the Pharmaceutical Research and Manufacturers of America (Babin, "Marketplace Morning Report," APM, 12/7). The complete segment is available online in RealPlayer. ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ..... About Us Privacy Policy Help Site Map Kaisernetwork.org is a free service of the Henry J. Kaiser Family Foundation. ... Prescription for Trouble: Consumer Reports Examines Weaknesses of ...... These include: - Rush to approve: Working under tight deadlines and with sometimes skimpy, unrepresentative data, the FDA reviews drugs at a pace that may make sound decisions difficult. Some FDA reviewers say that their bosses have pushed them to approve medications despite their reservations about safety. - A powerless FDA: The agency lacks the effective power to force companies to complete studies after drug approval, compel doctors to report adverse reactions, or dictate new warning labels. The agency's regulatory might also has been undercut by limited resources, dependency on drug company fees to help finance the review process, and what critics claim is a lack of will to enforce tough requirements. ... Consumer Reports Medical Guide & Consumer Reports: Prescription ...... These include: - Rush to approve: Working under tight deadlines and with sometimes skimpy, unrepresentative data, the FDA reviews drugs at a pace that may make sound decisions difficult. Some FDA reviewers say that their bosses have pushed them to approve medications despite their reservations about safety. - A powerless FDA: The agency lacks the effective power to force companies to complete studies after drug approval, compel doctors to report adverse reactions, or dictate new warning labels. The agency's regulatory might also has been undercut by limited resources, dependency on drug company fees to help finance the review process, and what critics claim is a lack of will to enforce tough requirements. - Ris... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news |
| Health and Fitness |